Paul Cottu
Overview
Explore the profile of Paul Cottu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
2442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer
Helal C, Djerroudi L, Ramtohul T, Laas E, Vincent-Salomon A, Jin M, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):15.
PMID: 39948122
Pathological complete response (pCR) after neoadjuvant chemoimmunotherapy (NACi) is associated with improved patient outcomes in early triple-negative breast cancer (TNBC). This study aimed to identify factors associated with pCR after...
2.
3.
Cottu P, Cheeseman S, Hall P, Wockel A, Scholz C, Bria E, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(2):419-430.
PMID: 39427280
Purpose: To characterize real-world attrition rates across first-line (1L) to third-line (3L) therapies in patients with HER2-positive (HER2 +) metastatic breast cancer (mBC) receiving routine care in seven hospital systems...
4.
Piffoux M, Jacquemin J, Petera M, Durand S, Abila A, Centeno D, et al.
Clin Cancer Res
. 2024 Aug;
30(20):4654-4666.
PMID: 39106085
Purpose: Long-term treatment-related toxicities, such as neurologic and metabolic toxicities, are major issues in breast cancer. We investigated the interest of metabolomic profiling to predict toxicities. Experimental Design: Untargeted high-resolution...
5.
Bouziane J, Loap P, Cottu P, Escalup L, Kirova Y
Am J Clin Oncol
. 2024 Jul;
47(12):574-579.
PMID: 38961527
Objectives: In the recent MONALEESA-2, MONALEESA-3, and MONALEESA-7 clinical trials, the addition of ribociclib, a CDK4/6 inhibitor, to standard endocrine therapy significantly improved progression-free survival (PFS) compared with hormone therapy...
6.
Camilleri G, Delrieu L, Bouleuc C, Pierga J, Cottu P, Berger F, et al.
Clin Nutr
. 2024 Jun;
43(8):1710-1718.
PMID: 38908032
Background: Malnutrition and sarcopenia are challenges for patients with metastatic breast cancer and have been proposed as independent prognostic factors. Very few studies have addressed the temporal evolution of these...
7.
Sandoval J, Franzoi M, Di Meglio A, Ferreira A, Viansone A, Andre F, et al.
J Clin Oncol
. 2024 Jun;
42(24):2908-2917.
PMID: 38889372
Purpose: Socioeconomic status (SES) influences the survival outcomes of patients with early breast cancer (EBC). However, limited research investigates social inequalities in their quality of life (QoL). This study examines...
8.
Soldato D, Michiels S, Havas J, Di Meglio A, Pagliuca M, Franzoi M, et al.
J Clin Oncol
. 2024 Jun;
42(25):3022-3032.
PMID: 38838281
Purpose: Postdiagnosis exercise is associated with lower breast cancer (BC) mortality but its link with risk of recurrence is less clear. We investigated the impact and dose-response relationship of exercise...
9.
Giacchetti S, Laas E, Bachelot T, Lemonnier J, Andre F, Cameron D, et al.
EBioMedicine
. 2024 May;
104:105141.
PMID: 38718683
Background: Circadian rhythms regulate cellular physiology and could influence the efficacy of endocrine therapy (ET) in breast cancer (BC). We prospectively tested this hypothesis within the UNIRAD adjuvant phase III...
10.
De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al.
Breast Cancer
. 2024 Apr;
31(4):572-580.
PMID: 38600429
Background: Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results. Methods: We set up an ambispective...